$PDSB
PDS Biotechnology Corp

2022 Q4 Form 10-Q Financial Statement

#000114036122041370 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.666M $2.926M $3.274M
YoY Change -9.08% -10.63% 76.99%
% of Gross Profit
Research & Development $16.16M $4.353M $3.688M
YoY Change 376.65% 18.03% 78.96%
% of Gross Profit
Depreciation & Amortization $11.58K $37.41K $1.280K
YoY Change 1118.95% 2822.66%
% of Gross Profit
Operating Expenses $18.82M $7.279M $6.962M
YoY Change 197.73% 4.55% 78.2%
Operating Profit -$7.279M -$6.962M
YoY Change 4.55% 78.2%
Interest Expense -$145.3K $1.360K
YoY Change -10780.44%
% of Operating Profit
Other Income/Expense, Net -$316.3K
YoY Change
Pretax Income -$19.14M -$7.424M -$6.961M
YoY Change 202.81% 6.66% 78.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.14M -$7.424M -$6.961M
YoY Change 202.81% 6.66% 78.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.26 -$0.24
Diluted Earnings Per Share -$0.66 -$0.26 -$244.9K
COMMON SHARES
Basic Shares Outstanding 28.51M 28.46M 28.42M
Diluted Shares Outstanding 28.46M 28.43M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.82M $71.64M $69.74M
YoY Change 13.15% 2.72% 108.19%
Cash & Equivalents $73.80M $71.60M $69.74M
Short-Term Investments
Other Short-Term Assets $2.660M $2.769M $1.597M
YoY Change 66.52% 73.4% 299.2%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $76.48M $74.41M $71.34M
YoY Change 14.42% 4.3% 110.8%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $407.2K
YoY Change -100.0% -100.0% 4257.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $527.5K $475.4K $407.2K
YoY Change 47.48% 16.75% -32.46%
TOTAL ASSETS
Total Short-Term Assets $76.48M $74.41M $71.34M
Total Long-Term Assets $527.5K $475.4K $407.2K
Total Assets $77.01M $74.89M $71.75M
YoY Change 14.6% 4.37% 108.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.219M $2.037M $1.446M
YoY Change -6.88% 40.94% -7.31%
Accrued Expenses $8.314M $2.429M $1.924M
YoY Change 280.02% 26.23% 57.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $56.61K $61.27K
YoY Change
Total Short-Term Liabilities $9.821M $4.841M $3.577M
YoY Change 161.47% 35.34% 23.41%
LONG-TERM LIABILITIES
Long-Term Debt $23.18M $22.99M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $314.0K
YoY Change -100.0% -100.0% -37.2%
Total Long-Term Liabilities $23.18M $22.99M $314.0K
YoY Change 9918.09% 7221.1% -37.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.821M $4.841M $3.577M
Total Long-Term Liabilities $23.18M $22.99M $314.0K
Total Liabilities $33.01M $27.83M $3.891M
YoY Change 727.74% 615.16% 14.44%
SHAREHOLDERS EQUITY
Retained Earnings -$101.6M -$82.42M
YoY Change 67.3%
Common Stock $9.956K $9.391K
YoY Change 6.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.00M $47.06M $67.86M
YoY Change
Total Liabilities & Shareholders Equity $77.01M $74.89M $71.75M
YoY Change 14.6% 4.37% 108.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$19.14M -$7.424M -$6.961M
YoY Change 202.81% 6.66% 78.22%
Depreciation, Depletion And Amortization $11.58K $37.41K $1.280K
YoY Change 1118.95% 2822.66%
Cash From Operating Activities -$7.529M -$5.893M -$5.129M
YoY Change 67.26% 14.9% 310.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.707M 24.55M 123.5K
YoY Change 97066400.04% 19777.48% -99.31%
NET CHANGE
Cash From Operating Activities -7.529M -5.893M -5.129M
Cash From Investing Activities
Cash From Financing Activities 9.707M 24.55M 123.5K
Net Change In Cash 2.178M 18.66M -5.005M
YoY Change -148.38% -472.77% -130.26%
FREE CASH FLOW
Cash From Operating Activities -$7.529M -$5.893M -$5.129M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37568
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4231384
dei Entity Address Address Line1
EntityAddressAddressLine1
25B Vreeland Road,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
208-3343
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00033 per share
dei Trading Symbol
TradingSymbol
PDSB
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28508688
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
231430
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-145254
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1358
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-65008
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2617
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7424450
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6960966
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22916077
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15115003
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1198905
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4516488
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
35747
CY2021Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48544998
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1701763
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
123507
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6960966
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
67856898
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7488
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47058836
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1344349
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1713741
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7424450
us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
0
us-gaap Pension Expense Reversal Of Expense Noncash
PensionExpenseReversalOfExpenseNoncash
35747
pdsb Increase Decrease In Finance Lease Right To Use Asset
IncreaseDecreaseInFinanceLeaseRightToUseAsset
306487
pdsb Increase Decrease In Finance Lease Right To Use Asset
IncreaseDecreaseInFinanceLeaseRightToUseAsset
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240799
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
188524
pdsb Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
138402
pdsb Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
0
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
25000000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
pdsb Fair Value Of Warrants Issued In Connection With Debt
FairValueOfWarrantsIssuedInConnectionWithDebt
1713741
pdsb Fair Value Of Warrants Issued In Connection With Debt
FairValueOfWarrantsIssuedInConnectionWithDebt
0
CY2020Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
100000000
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.75
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19000000
CY2020Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17100000
CY2021Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
4500000
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6088235
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.5
CY2021Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51700000
CY2021Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
48500000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2022Q3 pdsb Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
3
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1344350
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1701762
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3821924
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2400981
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0143
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9956
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0058
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0303
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0077
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.5588
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M28D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.58
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.43
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
55500
us-gaap Operating Lease Cost
OperatingLeaseCost
166500
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
52000
us-gaap Operating Lease Cost
OperatingLeaseCost
130493
us-gaap Interest Expense Debt
InterestExpenseDebt
374286
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
374286
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
72722
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
72722
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
119232
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
71214

Files In Submission

Name View Source Status
pdsb-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pdsb-20220930_cal.xml Edgar Link unprocessable
pdsb-20220930_def.xml Edgar Link unprocessable
pdsb-20220930_pre.xml Edgar Link unprocessable
brhc10043876_10q_htm.xml Edgar Link completed
0001140361-22-041370-index-headers.html Edgar Link pending
0001140361-22-041370-index.html Edgar Link pending
0001140361-22-041370.txt Edgar Link pending
0001140361-22-041370-xbrl.zip Edgar Link pending
brhc10043876_10q.htm Edgar Link pending
brhc10043876_ex10-1.htm Edgar Link pending
brhc10043876_ex10-2.htm Edgar Link pending
brhc10043876_ex31-1.htm Edgar Link pending
brhc10043876_ex31-2.htm Edgar Link pending
brhc10043876_ex32-1.htm Edgar Link pending
brhc10043876_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20220930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending